Compared with the oxaliplatin-sensitive group, the expression level of ciRS-122, which could target PKM2 to promote glycolysis, was higher in the oxaliplatin-resistant patient serum sEVs, revealing that the level of ciRS‐122 was positively associated with CRC oxaliplatin resistance [23]. This evidence concerns the gene PKM and colorectal carcinoma.